Objective:To analyze whether the application of growth hormone (GH) in the frozen-thawed embryo transfer (FET) cycle can improve the pregnancy outcome of patients.Methods:The retrospective cohort study including 1042 FET cycles was carried out between January 2015 to July 2018 in Reproductive Medicine Center,the Fourth Hospital of Hebei Medical University. According to medication before transfer, all patients were divided into GH group (group A ) and no GH group (group B). The pregnancy outcomes were compared between the two groups in aged patients (≥35 years), polycystic ovary syndrome (PCOS) patients and repeated implantation failure (RIF) patients.Results:In group A, the maternal age [(31.1±4.5) years old] and the clinical pregnancy rate [67.1% (114/170)] were higher than those in group B [(30.1±4.4) years old, 57.5% (501/872)]( P=0.010, P=0.020). There were no significant differences in the implantation rate, the clinical pregnancy rate, the abortion rate and the live birth rate between group A and group B in aged patients (all P>0.05). In PCOS patients, the live birth rate in group A [65.8% (25/38)] was significantly higher than that in group B [42.3% (96/227)] ( P=0.007). In the RIF patients, the implantation rate [37.3% (57/153)], the clinical pregnancy rate [50.5% (46/91)] and the live birth rate [37.4% (34/91)] in group A were significantly higher than those in group B [23.0% (115/501), 29.1% (92/316), 21.8% (69/316)] ( P<0.001, P<0.001, P=0.003). Conclusion:For the aged patients, adding GH could not improve pregnancy outcomes. The application of GH in PCOS patients could increase the live birth rate. For the RIF patients, the application of GH could increase the implantation rate, the clinical pregnancy rate and the live birth rate.

Objective:To analyze whether the application of growth hormone (GH) in the frozen-thawed embryo transfer (FET) cycle can improve the pregnancy outcome of patients.Methods:The retrospective cohort study including 1042 FET cycles was carried out between January 2015 to July 2018 in Reproductive Medicine Center,the Fourth Hospital of Hebei Medical University. According to medication before transfer, all patients were divided into GH group (group A ) and no GH group (group B). The pregnancy outcomes were compared between the two groups in aged patients (≥35 years), polycystic ovary syndrome (PCOS) patients and repeated implantation failure (RIF) patients.Results:In group A, the maternal age [(31.1±4.5) years old] and the clinical pregnancy rate [67.1% (114/170)] were higher than those in group B [(30.1±4.4) years old, 57.5% (501/872)]( P=0.010, P=0.020). There were no significant differences in the implantation rate, the clinical pregnancy rate, the abortion rate and the live birth rate between group A and group B in aged patients (all P>0.05). In PCOS patients, the live birth rate in group A [65.8% (25/38)] was significantly higher than that in group B [42.3% (96/227)] ( P=0.007). In the RIF patients, the implantation rate [37.3% (57/153)], the clinical pregnancy rate [50.5% (46/91)] and the live birth rate [37.4% (34/91)] in group A were significantly higher than those in group B [23.0% (115/501), 29.1% (92/316), 21.8% (69/316)] ( P<0.001, P<0.001, P=0.003). Conclusion:For the aged patients, adding GH could not improve pregnancy outcomes. The application of GH in PCOS patients could increase the live birth rate. For the RIF patients, the application of GH could increase the implantation rate, the clinical pregnancy rate and the live birth rate.